



Biotech Daily

Monday November 20, 2017

Daily news on ASX-listed biotechnology companies

- * **ASX, BIOTECH DOWN: ADMEDUS UP 8%; ACRUX DOWN 7%**
- * **SIMAVITA RAISES \$1.35m THROUGH CONVERTIBLE NOTES**
- * **GENERA RECEIVES \$489k FEDERAL R&D TAX INCENTIVE**
- * **HYDROPONICS: BREATH OF LIFE TO SUPPLY MARIJUANA PRODUCTS**
- * **NOXOPHARM: 10 OF 11 NOX66 PATIENTS 'NO CANCER PROGRESSION'**
- * **NOVOGEN NOW KAZIA, CODE CHANGE NOVEMBER 29**
- * **CRESO APPOINTS CHINA MARIJUANA DISTRIBUTOR**
- * **FMR TAKES 6% OF RESMED**
- * **DR DAX MARCUS CALDER, STAFFWEAR TAKE 11% OF PATRYS**
- * **BIOTRON LOSES 7-YEAR DIRECTOR DR DENIS WADE**

MARKET REPORT

The Australian stock market fell 0.19 percent on Monday November 20, 2017, with the ASX200 down 11.6 points to 5,945.7 points. Fifteen of the Biotech Daily Top 40 stocks were up, 17 fell, five traded unchanged and three were untraded. All three Big Caps rose.

Admedus was the best, up two cents or 8.3 percent to 26 cents with 1.2 million shares traded.

Actinogen climbed 5.9 percent; Avita improved 4.2 percent; Living Cell was up 3.1 percent; Clinuvel, ITL and Prana rose more than two percent; Airxpanders, Osprey, Polynovo, Sirtex, Starpharma, Universal Biosensors and Volpara were up more than one percent; with Cochlear, CSL, Pro Medicus and Resmed up by less than one percent.

Acrux led the falls, down one cent or 6.7 percent to 14 cents, with 5.8 million shares traded, followed by Neuren down 6.1 percent to 15.5 cents with 21.6 million shares traded.

Viralytics lost 4.7 percent; Genetic Signatures, Mesoblast, Opthea and Psivida were down more than three percent; Benitec, Dimerix, Ellex and Medical Developments shed more than two percent; with Bionomics, Factor Therapeutics, Impedimed, LBT, Nanosonics and Orthocell down by more than one percent.

SIMAVITA

Simavita says it has raised \$1,350,000 through the issue of secured, convertible notes at an interest rate of 10 percent a year convertible at four cents a share on July 31, 2018. Simavita said that in the event it had a further capital raising prior to July 31 2018, note holders had the option to convert at the new issue price.

The company said the noteholders were existing shareholders, including former director Damien Haakman's Dussman Pty Ltd which held 26 percent of Simavita, Parmelia Pty Ltd and Chevron with 8.8 percent, Robert Hutchison and Mary Ann McKenzie as trustees for the Inspiration Superannuation Fund with 5.54 percent and Michael Powell and Jolimont Lodge Pty Ltd as trustee for the Powell Superannuation Fund with 7.39 percent.

Simavita said the notes were secured through a general charge over its assets and the accrued interest would convert to shares.

The company said the funds would provide "a clear runway for the continued implementation of ... [its] strategy" which included commercialization of its Alertplus urinary incontinence management system.

Simavita said it was "actively pursuing licencing discussions with a number of major manufacturers in both North America and Europe".

Simavita was up 0.2 cents or 11.8 percent to 1.9 cents.

GENERA BIOSYSTEMS

Genera says it has received \$489,380 from the Australian Tax Office under the Federal Government Research and Development Tax Incentive program.

Genera said that the Tax Incentive related to expenditure in the year to June 30, 2017.

Genera was up two cents or 11.1 percent to 20 cents.

THE HYDROPONICS COMPANY

Hydroponics says it has letter of intent with the Revadim, Israel-based medical marijuana Breath Of Life Pharma to supply cannabinoid products in Australia.

Hydroponics chief executive officer David Radford said the partnership would provide "access to high-quality, targeted, medicinal cannabis products".

"This agreement reinforces our commitment to a dual supply strategy, importing some of the best cannabinoid related products to Australia, while cultivating our own medicinal cannabis strains in Australia," Mr Radford said.

Hydroponics said that through its Candeo subsidiary Breath Of Life (Bol) Pharma had agreed to supply all products required for an initial clinical trial with the view to provide products for additional clinical trials to take place during 2018.

Bol chief executive officer Dr Tamir Gedo said the agreement "kicks off Bol Pharma's entry into Australia's emerging medical cannabis market and supports our goal of bringing clinically-verified cannabinoid treatments to patients around the world".

"We are completely aligned with Candeo's objective of providing high quality, validated medical cannabis products to Australia and expect this agreement is just the beginning of long and productive collaboration," Dr Gedo said.

Hydroponics said that Bol sourced 99 percent pure pharmaceutical grade cannabidiol and tetrahydrocannabinol and other cannabinoids from its own certified cultivation facilities and certified production facility for patients, doctors and hospitals as well as formulations for research and white label services for the pharmaceuticals, supplements, and cosmetics industries.

Hydroponics was up 10 cents or 11.8 percent to 95 cents with eight million shares traded.

[NOXOPHARM](#)

Noxopharm says 10 of 11 patients in its 19-patient Georgia phase Ia/Ib trial of NOX66 with carboplatin have shown no disease progression after three months of treatment.

Noxopharm said that the trial was fully recruited with patients with late-stage, metastatic breast, ovarian, lung, prostate or head and neck solid cancers, who had failed standard treatments and had a minimum life-expectancy of three months.

The company said that each patient went through three steps from a three week period with NOX66 alone, then in combination with low-dose carboplatin for three months, ending with NOX66 and high-dose carboplatin for three months.

Noxopharm the 19 patients were divided into two cohorts with eight patients receiving 400mg NOX66 daily and 11 receiving 800mg NOX66 daily.

The company said that two patients dropped out voluntarily during the first step, one was withdrawn due to disease progression after the second step, one patient was withdrawn due to a severe adverse event in the third step and one patient completed all three steps and was off-study.

Noxopharm said the remaining 14 patients continued on-study, with the last patient due to have the six month scan in April 2018.

The company said that no adverse events were observed in the NOX66 alone step at either dosage, with no adverse events observed in 13 patients who completed the second step of NOX66 with low-dose carboplatin.

Noxopharm said that one serious adverse event, an infusion reaction, occurred in one patient following the first intravenous injection of high-dose carboplatin, leading to withdrawal of that patient from the study.

The company said that of 11 patients treated with NOX66 and low-dose carboplatin, only one showed disease progression after three months, one patient had disease progression, one had a partial response and nine had stable disease with no progression.

Noxopharm said that five of the 11 had 400mg NOX66 daily and six had 800mg NOX66 daily, with the one case of progressive lung cancer in the 400mg dose cohort, and the one case of partial prostate cancer response was in the 800mg dose cohort.

The company said the data was presented at the European Society of Medical Oncology Asia meeting in Singapore on November 18, 2017.

Noxopharm was up 20.5 cents or 31.8 percent to 85 cents with 1.1 million shares traded.

[KAZIA THERAPEUTICS \(FORMERLY NOVOGEN\)](#)

Novogen says that following shareholder and Australian Securities and Investments Commission approval, the name Kazia Therapeutics has been formally adopted.

Kazia said it would trade under the new code of KZA from November 29, 2017 following the 10-for-one share consolidation, and on the Nasdaq under the code of KZIA.

The company said that from November 17 shares would trade as NRTDA, with options trading as NRTDB.

Kazia said that from November 28, its shares would return to NRT, with options as NRTO. The company said that from November 29, its shares would trade as KZA, with options as KZAO

Kazia chief executive officer Dr James Garner said the new brand reflected “the innovative, focused and agile company that we have become”.

Kazia fell half a cent or 1.4 percent to 35 cents.

CRESO PHARMA

Creso says it has a hemp and marijuana distribution agreement with China's Zhejiang Kingdom Creative Co.

Creso said that Zhejiang Kingdom Creative Co was a subsidiary of the Hong Kong Stock Exchange-listed Kingdom Group and had revenue for the six months to June 30, 2017 of RMB454.8 million (\$A90.6 million) and the deal would provide it "with a strategic foothold in China" allowing Kingdom Creative to expand its product range to the healthcare sector using Creso's hemp and cannabis food additives, cosmetics and medical marijuana therapeutics and products.

The company said that Kingdom Creative would import its human and animal health marijuana-derived products and invest in the marketing and distribution of the products. Creso said it had opened offices in Beijing, Shanghai, Shenzhen and Guangzhou to give it a sales and marketing presence and distribution network.

Creso was up 17 cents or 20.7 percent to 99 cents with 6.5 million shares traded.

RESMED

Fidelity Management & Research (FMR) says it has increased its substantial shareholding in Resmed from 7,123,933 shares (5.01%) to 8,552,087 shares (6.03%).

The Boston, Massachusetts-based FMR previously said it was a related party to Fidelity International Limited (FIL) with investments in Acrux, Cochlear, CSL and Heartware. FMR said it bought and sold shares between August 17 and November 15, 2017 in more than 900 trades at prices from \$A73.07 to \$A85.78 per US share.

Biotech Daily believes that the prices were in US dollars, not Australian as cited, and at the US rate that would be the equivalent of \$A9.67 to \$A11.35 per Australian Chess depository instrument (CDIs).

Resmed was up three cents or 0.3 percent to \$11.17 with two million shares traded.

PATRY'S

Dr Dax Marcus Calder has increased his substantial shareholding in Patrys from 70,521,428 shares (9.46%) to 87,026,226 shares (11.16%).

The substantial shareholder notice said that the West Perth, Western Australia-based Dr Calder acquired 10,478,572 shares directly and with Staffwear Pty Ltd between October 30 and November 15, 2017 for \$203,613 or an average price of 1.9 cents a share.

The notice said that Staffwear acquired 6,026,226 shares between September 29 and December 5, 2014 for \$108,943 or 1.8 cents a share.

Patrys was unchanged at 1.9 cents.

BIOTRON

Biotron says that director Dr Denis Wade has resigned, effective from the close of today's annual general meeting "due to personal reasons".

Biotron said that Dr Wade was appointed as a director in 2010 (BD: Apr 30, 2010).

Biotron fell 0.3 cents or 8.3 percent to 3.3 cents with 1.7 million shares traded.